Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Accounting firms today are at a crossroads. While client demands, regulatory pressures, and workloads have evolved dramatically, the tools used to handle ...

Key Points OJEMDA net product revenue surged 310% year over year to $33.6 million in Q2 2025, driving total quarterly revenue (GAAP) to $33.9 million but narrowly missed consensus expectations for ...

The SWAYAM platform is an initiative by the Government of India, is designed to bridge the digital divide and democratize ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing ...

Good morning, and welcome to the Icahn Enterprises L.P. Second Quarter 2025 Earnings Call with Andrew Teno, President and CEO and and Ted Papapostolou, Chief Financial Officer; and Robert Flint, Chief ...

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported ...

Cryptocurrency is far more than a passing craze or a speculative investment vehicle. It is a revolution in our understanding ...

Syndax Pharmaceuticals, Inc. ( NASDAQ: SNDX) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET ...

Q2 2025 Earnings Call Transcript August 1, 2025 Fulgent Genetics, Inc. misses on earnings expectations. Reported EPS is $-0.62065 EPS, expectations were $-0.23. Operator: Greetings, and welcome to the ...